Precision Medicine in Prostate Cancer VL

rPFS Improvement Regardless of Mutations in Biomarker Subgroups in the Phase III PROpel Trial in First-Line Therapy for Patients with mCRPC - Fred Saad

Details
Fred Saad joins Alicia Morgans in a discussion focusing on the biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). This updated analysis provides more detail on patients with HRR mutations in the PROpel trial. In this biomarker a...

Extending Prostate Genetic Awareness, Navigation and Delivery for Genetic Testing in Males of African American Decent - The EXPAND Network - Veda Giri

Details
Veda Giri joins Charles Ryan in a discussion on the EXPAND Network, EX tending P rostate Cancer Genetic A wareness, N avigation, and D elivery for genetic testing, and genetic awareness in males of African descent for Black men. This project is supported by the 2021 PCF-Pfizer Health Equity Challenge Award grant mechanism. Dr. Giri provides the rationale for this project stemming from statistics f...

BRCAAway - a Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with mCRPC with DNA Repair Defects - Maha Hussain

Details
Maha Hussain is discussing the BRCAAway with Alicia Morgans, based upon Dr Hussain's presentation at ASCO 2022. The BRCAAway Trial is a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with mCRPC with DNA repair defects either in the tumor or germline. The PARP-inhibitor olaparib is approved for mCRPC patients with deleterious germline or somatic homologous...

Impact of Next Generation Imaging: What Is the Optimal (Current) Tracer for PET-Based Imaging for Staging Presentation - Ken Herrmann

Details
Ken Herrmann presents an update on the current data regarding optimal PSMA PET tracers. Biographies: Ken Herrmann, MD, MBA, Professor and Chair of the Department of Nuclear Medicine, Universitatsklinikum Essen, Essen, Germany Related Content: APCCC 2022: Impact of Next Generation Imaging: What Is the Optimal (Current) Tracer for PET-Based Imaging for Staging The Mechanism of PSMA PET for Prostate...

Integrating 177Lu-PSMA-617 in Clinical Practice - Oliver Sartor

Details
Oliver Sartor joins Alicia Morgans in a discussion on implementation strategies for integrating Lutetium-177 (177Lu-PSMA-617) into clinical practices and the challenges that we're facing with availability issues. Biographies: A. Oliver Sartor, MD, Professor of Medicine and Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Research, New Orleans, Louisiana Alici...

The Use of PARP Inhibitors in Castrate-Resistant Prostate Cancer - Elena Castro & Joaquin Mateo

Details
Elena Castro and Joaquin Mateo join Alicia Morgans in a conversation on data related to genetic testing, PARP inhibitors, and the data we saw come out of GU ASCO with the PROpel and MAGNITUDE trials and they discuss how this data impacts the use of PARP inhibitors in castrate-resistant prostate cancer (CRPC). Drs. Castro, Mateo, and Morgans discuss this data in terms of next-generation sequencing...

Hereditary Cancer Risk Assessment For Prostate Cancer Patients - Neal Shore

Details
Joining Alicia Morgans is Neal Shore to further highlight his team's presentation at this year's GU ASCO 2022 Annual Meeting focusing on evaluating the feasibility of instituting a hereditary cancer risk assessment (HCRA) protocol in their urological practice for prostate cancer patients. The results found were encouraging for the incorporation of recommended genomic screenings in community urolog...

Integration of Pluvicto™ (177Lu-PSMA-617) in Clinical Practice - Oliver Sartor and Kendra Harris

Details
Drs Oliver Sartor and Kendra Harris join Phillip Koo to discuss the clinical implications and integration of Pluvicto™ into clinical practice and offer guidance to clinicians looking to implement this therapy in their clinics. Pluvicto™ (177Lu-PSMA-617) is the first FDA-approved targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer. Biographies: A. Olive...

The Efficacy and Safety of Olaparib + Abiraterone in the First-Line mCRPC Setting PROpel – Fred Saad

Details
Fred Saad joins Alicia Morgans to discuss the results of the PROpel phase 3 trial of olaparib and abiraterone versus placebo and abiraterone as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Biographies: Fred Saad, MD, FRCS, Professor and Chief of Urology, Director of GU Oncology, Raymond Garneau Chair in Prostate Cancer, University of Montreal Hospit...

Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell

Details
Kara Maxwell and Alicia Morgans discuss DNA repair defect alterations in patients with localized prostate cancer. Dr. Maxwell highlights DNA repair in conjunction with prostate cancer, as well as the Penn Medicine BioBank. The conversation concludes with a discussion on the future of prostate cancer genomics. Biographies: Kara N. Maxwell, MD, Ph.D., Assistant Professor of Medicine and Genetics, Un...
email news signup